Dihydrolycorine
CAS No. 6271-21-2
Dihydrolycorine( —— )
Catalog No. M18922 CAS No. 6271-21-2
Dihydrolycorine-HCL(DL) shows hypotensive effects, it can block alpha 1-adrenoceptors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 55 | In Stock |
|
| 2MG | 28 | In Stock |
|
| 5MG | 45 | In Stock |
|
| 10MG | 78 | In Stock |
|
| 25MG | 123 | In Stock |
|
| 50MG | 183 | In Stock |
|
| 100MG | 326 | In Stock |
|
| 200MG | 456 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDihydrolycorine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDihydrolycorine-HCL(DL) shows hypotensive effects, it can block alpha 1-adrenoceptors.
-
DescriptionDihydrolycorine-HCL(DL) shows hypotensive effects, it can block alpha 1-adrenoceptors. Dihydrolycorine is an inhibitors of protein synthesis in eukarytic cells, it halts protein synthesis in eukaryotic cells by inhibiting the peptide bone formation step. Dihydrolycorine and nimodipine protects against anoxia damage of brain in rat.
-
In Vitro——
-
In VivoDihydrolycorine inhibits methoxamine-induced contraction of isolated rabbit aortic rings and rat anococcygeus muscle with pA2 values of 5.93 and 6.35, respectively.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number6271-21-2
-
Formula Weight289.33
-
Molecular FormulaC16H19NO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (43.20 mM)
-
SMILESC1CN2CC3=CC4=C(C=C3C5C2C1CC(C5O)O)OCO4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Britannin
Britannin a sesquiterpene lactone inhibits proliferation and induces apoptosis through the mitochondrial signaling pathway in human breast cancer cells.
-
Flavokawain C
Flavokawain C (FKC) a naturally occurring chalcone which can be isolated from Kava.FKC has the potential to be developed into chemotherapeutic drug for the treatment of colon adenocarcinoma.
-
Lexatumumab
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma.
Cart
sales@molnova.com